{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:46:50Z","timestamp":1793134010121,"version":"4.5.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41440-024-01989-w","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T10:45:09Z","timestamp":1731581109000},"page":"284-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management"],"prefix":"10.1038","volume":"48","author":[{"given":"Maya K.","family":"Jangid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-0705","authenticated-orcid":false,"given":"Gaurav M.","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"publisher","first-page":"115968","DOI":"10.1016\/j.biopha.2023.115968","volume":"170","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Zhou Z-Y, Sun J-C, Xing W, Yan J, Xu W-J, et al. Protective effect of novel angiotensin receptor neprilysin inhibitor S086 on target organ injury in spontaneously hypertensive rats. Biomed Pharmacother. 2024;170:115968. https:\/\/doi.org\/10.1016\/j.biopha.2023.115968.","journal-title":"Biomed Pharmacother"},{"key":"1989_CR2","doi-asserted-by":"publisher","unstructured":"Cerrudo CS, Cavallero S, Rodr\u00edguez Fermep\u00edn M, Gonz\u00e1lez GE, Donato M, Kouyoumdzian NM, et al. Cardiac Natriuretic Peptide Profiles in Chronic Hypertension by Single or Sequentially Combined Renovascular and DOCA-Salt Treatments. Front Physiol. 2021;12. https:\/\/doi.org\/10.3389\/fphys.2021.651246.","DOI":"10.3389\/fphys.2021.651246"},{"key":"1989_CR3","doi-asserted-by":"crossref","unstructured":"Ganguly A, Sharma K, Majumder K. Food-derived bioactive peptides and their role in ameliorating hypertension and associated cardiovascular diseases. 2019, 165\u2013207.","DOI":"10.1016\/bs.afnr.2019.04.001"},{"key":"1989_CR4","doi-asserted-by":"publisher","first-page":"104168","DOI":"10.1016\/j.lpm.2023.104168","volume":"52","author":"A Boucly","year":"2023","unstructured":"Boucly A, Gerges C, Savale L, Ja\u00efs X, Jevnikar M, Montani D, et al. Pulmonary arterial hypertension. Presse Med. 2023;52:104168. https:\/\/doi.org\/10.1016\/j.lpm.2023.104168.","journal-title":"Presse Med"},{"key":"1989_CR5","doi-asserted-by":"publisher","first-page":"171170","DOI":"10.1016\/j.peptides.2024.171170","volume":"175","author":"M Alauddin","year":"2024","unstructured":"Alauddin M, Amin MDR, Siddiquee MA, Hiwatashi K, Shimakage A, Takahashi S, et al. In silico and in vivo experiment of soymilk peptide (tetrapeptide - FFYY) for the treatment of hypertension. Pept (NY). 2024;175:171170. https:\/\/doi.org\/10.1016\/j.peptides.2024.171170.","journal-title":"Pept (NY)"},{"key":"1989_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41440-021-00643-z","volume":"44","author":"T Ghatage","year":"2021","unstructured":"Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. Hypertens Res. 2021;44:740\u201355. https:\/\/doi.org\/10.1038\/s41440-021-00643-z.","journal-title":"Hypertens Res"},{"key":"1989_CR7","doi-asserted-by":"publisher","unstructured":"Ranasinghe P, Addison ML, Webb DJ. Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor\u2010Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen\u2013Targeting Small Interfering RNA. J Am Heart Assoc. 2022;11. https:\/\/doi.org\/10.1161\/JAHA.122.027694.","DOI":"10.1161\/JAHA.122.027694"},{"key":"1989_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.117.028388","volume":"136","author":"AA Aubdool","year":"2017","unstructured":"Aubdool AA, Thakore P, Argunhan F, Smillie S-J, Schnelle M, Srivastava S, et al. A Novel \u03b1-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure. Circulation. 2017;136:367\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028388.","journal-title":"Circulation"},{"key":"1989_CR9","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.3390\/ijms20133265","volume":"20","author":"V Cannone","year":"2019","unstructured":"Cannone V, Cabassi A, Volpi R, Burnett JC. Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease. Int J Mol Sci. 2019;20:3265. https:\/\/doi.org\/10.3390\/ijms20133265.","journal-title":"Int J Mol Sci"},{"key":"1989_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.peptides.2008.02.005","volume":"29","author":"F Hong","year":"2008","unstructured":"Hong F, Ming L, Yi S, Zhanxia L, Yongquan W, Chi L. The antihypertensive effect of peptides: A novel alternative to drugs? Pept (NY). 2008;29:1062\u201371. https:\/\/doi.org\/10.1016\/j.peptides.2008.02.005.","journal-title":"Pept (NY)"},{"key":"1989_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40292-021-00483-5","volume":"29","author":"S Rubattu","year":"2022","unstructured":"Rubattu S, Gallo G. The Natriuretic Peptides for Hypertension Treatment. High Blood Press Cardiovasc Prev. 2022;29:15\u201321. https:\/\/doi.org\/10.1007\/s40292-021-00483-5.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1989_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1573403X15666190625160352","volume":"16","author":"J Salazar","year":"2020","unstructured":"Salazar J, Rojas-Quintero J, Cano C, P\u00e9rez JL, Ram\u00edrez P, Carrasquero R, et al. Neprilysin: A Potential Therapeutic Target of Arterial Hypertension? Curr Cardiol Rev. 2020;16:25\u201335. https:\/\/doi.org\/10.2174\/1573403X15666190625160352.","journal-title":"Curr Cardiol Rev"},{"key":"1989_CR13","doi-asserted-by":"publisher","unstructured":"Lang C, Singh J. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag. 2015;283. https:\/\/doi.org\/10.2147\/VHRM.S55630.","DOI":"10.2147\/VHRM.S55630"},{"key":"1989_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1096\/fj.03-0428com","volume":"18","author":"S Cuzzocrea","year":"2004","unstructured":"Cuzzocrea S, Mazzon E, Dugo L, Di Paola R, Caputi AP, Salvemini D. Superoxide: a key player in hypertension. FASEB J. 2004;18:94\u2013101. https:\/\/doi.org\/10.1096\/fj.03-0428com.","journal-title":"FASEB J"},{"key":"1989_CR15","doi-asserted-by":"publisher","unstructured":"Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, et al. Hypertension: physiology and pathophysiology. Compr Physiol. Hoboken, New Jersey, USA: Wiley Online Library; 2012;2:2393\u2013442. https:\/\/doi.org\/10.1002\/cphy.c110058.","DOI":"10.1002\/cphy.c110058"},{"key":"1989_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/hy09t1.096249","volume":"38","author":"HD Intengan","year":"2001","unstructured":"Intengan HD, Schiffrin EL. Vascular Remodeling in Hypertension. Hypertension. 2001;38:581\u20137. https:\/\/doi.org\/10.1161\/hy09t1.096249.","journal-title":"Hypertension"},{"key":"1989_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cardiores.2006.05.001","volume":"71","author":"T Paravicini","year":"2006","unstructured":"Paravicini T, Touyz R. Redox signaling in hypertension. Cardiovasc Res. 2006;71:247\u201358. https:\/\/doi.org\/10.1016\/j.cardiores.2006.05.001.","journal-title":"Cardiovasc Res"},{"key":"1989_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/hr.2011.39","volume":"34","author":"E Schulz","year":"2011","unstructured":"Schulz E, Gori T, M\u00fcnzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665\u201373. https:\/\/doi.org\/10.1038\/hr.2011.39.","journal-title":"Hypertens Res"},{"key":"1989_CR19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/bmj.322.7291.912","volume":"322","author":"G Beevers","year":"2001","unstructured":"Beevers G. ABC of hypertension: The pathophysiology of hypertension. BMJ. 2001;322:912\u20136. https:\/\/doi.org\/10.1136\/bmj.322.7291.912.","journal-title":"BMJ"},{"key":"1989_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/01.CIR.87.2.464","volume":"87","author":"M Yoshimura","year":"1993","unstructured":"Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464\u20139. https:\/\/doi.org\/10.1161\/01.CIR.87.2.464.","journal-title":"Circulation"},{"key":"1989_CR21","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","volume":"50","author":"LB Daniels","year":"2007","unstructured":"Daniels LB, Maisel AS. Natriuretic Peptides. J Am Coll Cardiol. 2007;50:2357\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.021.","journal-title":"J Am Coll Cardiol"},{"key":"1989_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12917-022-03548-2","volume":"18","author":"Z Khaki","year":"2022","unstructured":"Khaki Z, Nooshirvani P, Shirani D, Masoudifard M. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease. BMC Vet Res. 2022;18:448. https:\/\/doi.org\/10.1186\/s12917-022-03548-2.","journal-title":"BMC Vet Res"},{"key":"1989_CR23","doi-asserted-by":"publisher","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","volume":"227","author":"K Kuwahara","year":"2021","unstructured":"Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharm Ther. 2021;227:107863. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107863.","journal-title":"Pharm Ther"},{"key":"1989_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jointm.2022.05.004","volume":"2","author":"K Zhang","year":"2022","unstructured":"Zhang K, Cao L, Xuan N, Huang T, Tian B, Cui W, et al. The effect of renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies. J Intensive Med. 2022;2:282\u201390. https:\/\/doi.org\/10.1016\/j.jointm.2022.05.004.","journal-title":"J Intensive Med"},{"key":"1989_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317\u201325. https:\/\/doi.org\/10.1016\/j.biopha.2017.07.091.","journal-title":"Biomed Pharmacother"},{"key":"1989_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.118.11081","volume":"72","author":"J Jordan","year":"2018","unstructured":"Jordan J, Birkenfeld AL, Melander O, Moro C. Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk. Hypertension. 2018;72:270\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11081.","journal-title":"Hypertension"},{"key":"1989_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.autneu.2009.03.005","volume":"148","author":"APM Yusof","year":"2009","unstructured":"Yusof APM, Yusoff NHM, Suhaimi FW, Coote JH. Role of supraspinal vasopressin neurones in the effects of atrial natriuretic peptide on sympathetic nerve activity. Autonomic Neurosci. 2009;148:50\u201354. https:\/\/doi.org\/10.1016\/j.autneu.2009.03.005.","journal-title":"Autonomic Neurosci"},{"key":"1989_CR28","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3390\/ijms20081820","volume":"20","author":"Z Cao","year":"2019","unstructured":"Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int J Mol Sci. 2019;20:1820. https:\/\/doi.org\/10.3390\/ijms20081820.","journal-title":"Int J Mol Sci"},{"key":"1989_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.CIR.90.1.195","volume":"90","author":"H Yasue","year":"1994","unstructured":"Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195\u2013203. https:\/\/doi.org\/10.1161\/01.CIR.90.1.195.","journal-title":"Circulation"},{"key":"1989_CR30","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.1016\/j.ijcha.2023.101282","volume":"49","author":"N Ueda","year":"2023","unstructured":"Ueda N, Kataoka N, Miyazaki Y, Shimamoto K, Wakamiya A, Nakajima K, et al. N-terminal pro atrial natriuretic peptide as a prognostic marker of cardiac resynchronization therapy recipients. IJC Heart Vasculature. 2023;49:101282. https:\/\/doi.org\/10.1016\/j.ijcha.2023.101282.","journal-title":"IJC Heart Vasculature"},{"key":"1989_CR31","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/309724a0","volume":"309","author":"S Oikawa","year":"1984","unstructured":"Oikawa S, Imai M, Ueno A, Tanaka S, Noguchi T, Nakazato H, et al. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic poly peptide. Nature. 1984;309:724\u20136. https:\/\/doi.org\/10.1038\/309724a0.","journal-title":"Nature"},{"key":"1989_CR32","doi-asserted-by":"publisher","unstructured":"Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341\u201366. https:\/\/doi.org\/10.1007\/978-3-540-68964-5_15.","DOI":"10.1007\/978-3-540-68964-5_15"},{"key":"1989_CR33","doi-asserted-by":"publisher","first-page":"8525","DOI":"10.1073\/pnas.150149097","volume":"97","author":"W Yan","year":"2000","unstructured":"Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci. 2000;97:8525\u20139. https:\/\/doi.org\/10.1073\/pnas.150149097.","journal-title":"Proc Natl Acad Sci"},{"key":"1989_CR34","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/01.CIR.88.3.1004","volume":"88","author":"CM Wei","year":"1993","unstructured":"Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, et al. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004\u20139. https:\/\/doi.org\/10.1161\/01.CIR.88.3.1004.","journal-title":"Circulation"},{"key":"1989_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/B978-0-12-816061-9.00013-8","volume-title":"In Principles and Applications of Molecular Diagnostics","author":"DJ Dietzen","year":"2018","unstructured":"Dietzen DJ. Amino Acids, Peptides, and Proteins. In Principles and Applications of Molecular Diagnostics. Elsevier; 2018. p. 345\u201380."},{"key":"1989_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cardiores.2005.06.008","volume":"68","author":"J Dietz","year":"2005","unstructured":"Dietz J. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res. 2005;68:8\u201317. https:\/\/doi.org\/10.1016\/j.cardiores.2005.06.008.","journal-title":"Cardiovasc Res"},{"key":"1989_CR37","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s001090050179","volume":"75","author":"H Ruskoaho","year":"1997","unstructured":"Ruskoaho H, Leskinen H, Magga J, Taskinen P, M\u00e4ntymaa P, Vuolteenaho O, et al. Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide, and angiotensin II. J Mol Med. 1997;75:876\u201385. https:\/\/doi.org\/10.1007\/s001090050179.","journal-title":"J Mol Med"},{"key":"1989_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0008-6363(01)00238-3","volume":"51","author":"T Suzuki","year":"2001","unstructured":"Suzuki T. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res. 2001;51:489\u201394. https:\/\/doi.org\/10.1016\/S0008-6363(01)00238-3.","journal-title":"Cardiovasc Res"},{"key":"1989_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00004872-199715080-00004","volume":"15","author":"MB Anand-Srivastava","year":"1997","unstructured":"Anand-Srivastava MB. Atrial natriuretic peptide-C receptor and membrane signalling in hypertension. J Hypertens. 1997;15:815\u201326. https:\/\/doi.org\/10.1097\/00004872-199715080-00004.","journal-title":"J Hypertens"},{"key":"1989_CR40","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1210\/endo.138.5.5120","volume":"138","author":"H Leskinen","year":"1997","unstructured":"Leskinen H, Vuolteenaho O, Toth M, Ruskoaho H. Atrial Natriuretic Peptide (ANP) Inhibits Its Own Secretion via ANPA Receptors: Altered Effect in Experimental Hypertension*. Endocrinology. 1997;138:1893\u2013902. https:\/\/doi.org\/10.1210\/endo.138.5.5120.","journal-title":"Endocrinology"},{"key":"1989_CR41","doi-asserted-by":"crossref","unstructured":"Steinh\u00e4user C, Kettenmann H. Astrocyte: Neurotransmitter and Hormone Receptors. In Encyclopedia of Neuroscience. Amsterdam, Netherlands: Elsevier; 2009. p. 579\u201385.","DOI":"10.1016\/B978-008045046-9.01020-2"},{"key":"1989_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/er.2005-0014","volume":"27","author":"LR Potter","year":"2006","unstructured":"Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions. Endocr Rev. 2006;27:47\u201372. https:\/\/doi.org\/10.1210\/er.2005-0014.","journal-title":"Endocr Rev"},{"key":"1989_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47710-8","volume":"13","author":"WF Ang","year":"2023","unstructured":"Ang WF, Liao D, Koh CY, Kini RM. Unveiling the potential role of natriuretic peptide receptor a isoforms in fine-tuning the cGMP production and tissue-specific function. Sci Rep. 2023;13:20439. https:\/\/doi.org\/10.1038\/s41598-023-47710-8.","journal-title":"Sci Rep"},{"key":"1989_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-017-0093-0","volume":"12","author":"S Fu","year":"2018","unstructured":"Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2. https:\/\/doi.org\/10.1186\/s13036-017-0093-0.","journal-title":"J Biol Eng"},{"key":"1989_CR45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","volume":"45","author":"T Soeki","year":"2005","unstructured":"Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005;45:608\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2004.10.067.","journal-title":"J Am Coll Cardiol"},{"key":"1989_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s43168-022-00132-y","volume":"16","author":"B Nicolae","year":"2022","unstructured":"Nicolae B, Ecaterina L. Natriuretic peptides in elderly patients with chronic obstructive pulmonary disease. Egypt J Bronchol. 2022;16:26. https:\/\/doi.org\/10.1186\/s43168-022-00132-y.","journal-title":"Egypt J Bronchol"},{"key":"1989_CR47","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","volume":"34","author":"S Mangiafico","year":"2013","unstructured":"Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34:886\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehs262.","journal-title":"Eur Heart J"},{"key":"1989_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"M Volpe","year":"2015","unstructured":"Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci. 2015;130:57\u201377. https:\/\/doi.org\/10.1042\/CS20150469.","journal-title":"Clin Sci"},{"key":"1989_CR49","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.3390\/ijms20163991","volume":"20","author":"S Rubattu","year":"2019","unstructured":"Rubattu S, Volpe M. Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. Int J Mol Sci. 2019;20:3991. https:\/\/doi.org\/10.3390\/ijms20163991.","journal-title":"Int J Mol Sci"},{"key":"1989_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/378065a0","volume":"378","author":"MJ Lopez","year":"1995","unstructured":"Lopez MJ, Wong SK-F, Kishimoto I, Dubois S, Mach V, Friesen J, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65\u201368. https:\/\/doi.org\/10.1038\/378065a0.","journal-title":"Nature"},{"key":"1989_CR51","doi-asserted-by":"publisher","first-page":"R624","DOI":"10.1152\/ajpregu.00324.2010","volume":"300","author":"T Matsukawa","year":"2011","unstructured":"Matsukawa T, Miyamoto T. Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol. 2011;300:R624\u2013R629. https:\/\/doi.org\/10.1152\/ajpregu.00324.2010.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1989_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1152\/advan.00177.2016","volume":"41","author":"PCY Wong","year":"2017","unstructured":"Wong PCY, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017;41:179\u201385. https:\/\/doi.org\/10.1152\/advan.00177.2016.","journal-title":"Adv Physiol Educ"},{"key":"1989_CR53","doi-asserted-by":"publisher","first-page":"101132","DOI":"10.1016\/j.ijcha.2022.101132","volume":"43","author":"B Kerr","year":"2022","unstructured":"Kerr B, Brandon L. Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP \u2013 A narrative review. IJC Heart Vasculature. 2022;43:101132. https:\/\/doi.org\/10.1016\/j.ijcha.2022.101132.","journal-title":"IJC Heart Vasculature"},{"key":"1989_CR54","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","volume":"278","author":"LR Potter","year":"2011","unstructured":"Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808\u201317. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08082.x.","journal-title":"FEBS J"},{"key":"1989_CR55","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3390\/ijms20092092","volume":"20","author":"M Volpe","year":"2019","unstructured":"Volpe M, Rubattu S, Battistoni A. ARNi: A Novel Approach to Counteract Cardiovascular Diseases. Int J Mol Sci. 2019;20:2092. https:\/\/doi.org\/10.3390\/ijms20092092.","journal-title":"Int J Mol Sci"},{"key":"1989_CR56","doi-asserted-by":"publisher","unstructured":"Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care. 2004;10:336\u201341. https:\/\/doi.org\/10.1097\/01.ccx.0000135513.26376.4f.","DOI":"10.1097\/01.ccx.0000135513.26376.4f"},{"key":"1989_CR57","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016;133:1115\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018622.","journal-title":"Circulation"},{"key":"1989_CR58","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1056\/NEJM199703203361203","volume":"336","author":"RL Allgren","year":"1997","unstructured":"Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, et al. Anaritide in Acute Tubular Necrosis. N Engl J Med. 1997;336:828\u201334. https:\/\/doi.org\/10.1056\/NEJM199703203361203.","journal-title":"N Engl J Med"},{"key":"1989_CR59","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","volume":"76","author":"M Emdin","year":"2020","unstructured":"Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF, et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. J Am Coll Cardiol. 2020;76:1795\u2013807. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.031.","journal-title":"J Am Coll Cardiol"},{"key":"1989_CR60","doi-asserted-by":"publisher","unstructured":"Suzuki S, Aoki Y, Anezaki H, Wakuda C, Oshima S, Nishimoto H, et al. Association Between the Presence of Pulmonary Hypertension Before Cardiovascular Surgery and the Nephroprotective Effect of Carperitide: A Retrospective Cohort Study. Cureus. 2022; https:\/\/doi.org\/10.7759\/cureus.22891.","DOI":"10.7759\/cureus.22891"},{"key":"1989_CR61","doi-asserted-by":"publisher","unstructured":"Toshinari A, Chigusa Y, Yamaguchi A, Takakura M, Komatsu M, Morita M, et al. Administration of carperitide in cases of pulmonary edema with preeclampsia: a pilot case series. Hypertens Res Pregnancy. 2024: HRP2024-001. https:\/\/doi.org\/10.14390\/jsshp.HRP2024-001.","DOI":"10.14390\/jsshp.HRP2024-001"},{"key":"1989_CR62","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1053\/j.jvca.2015.04.022","volume":"29","author":"Y Sasabuchi","year":"2015","unstructured":"Sasabuchi Y, Yasunaga H, Matsui H, Lefor AK, Fushimi K, Sanui M. Carperitide Increases the Need for Renal Replacement Therapy After Cardiovascular Surgery. J Cardiothorac Vasc Anesth. 2015;29:1426\u201331. https:\/\/doi.org\/10.1053\/j.jvca.2015.04.022.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1989_CR63","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.cpcardiol.2023.102180","volume":"49","author":"MP Sousa","year":"2024","unstructured":"Sousa MP, Bettencourt P, Br\u00e1s-Silva C, Pereira C. Biosensors for natriuretic peptides in cardiovascular diseases. A review. Curr Probl Cardiol. 2024;49:102180. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102180.","journal-title":"Curr Probl Cardiol"},{"key":"1989_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jjcc.2015.09.011","volume":"67","author":"A Sezai","year":"2016","unstructured":"Sezai A, Shiono M. Natriuretic peptides for perioperative management of cardiac surgery. J Cardiol. 2016;67:15\u201321. https:\/\/doi.org\/10.1016\/j.jjcc.2015.09.011.","journal-title":"J Cardiol"},{"key":"1989_CR65","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/hr.2014.70","volume":"37","author":"H Asanuma","year":"2014","unstructured":"Asanuma H, Sanada S, Asakura M, Asano Y, Kim J, Shinozaki Y, et al. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. Hypertens Res. 2014;37:716\u201323. https:\/\/doi.org\/10.1038\/hr.2014.70.","journal-title":"Hypertens Res"},{"key":"1989_CR66","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijcard.2018.06.002","volume":"281","author":"T Ichiki","year":"2019","unstructured":"Ichiki T, Dzhoyashvili N, Burnett JC. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol. 2019;281:166\u201371. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.002.","journal-title":"Int J Cardiol"},{"key":"1989_CR67","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ehjcvp\/pvv043","volume":"2","author":"J Wojta","year":"2016","unstructured":"Wojta J. Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. Eur Heart J Cardiovasc Pharmacother. 2016;2:106\u20137. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv043.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1989_CR68","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"Packer M, O\u2019Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med. 2017;376:1956\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1601895.","journal-title":"N Engl J Med"},{"key":"1989_CR69","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijcard.2019.01.049","volume":"280","author":"T Nagai","year":"2019","unstructured":"Nagai T, Iwakami N, Nakai M, Nishimura K, Sumita Y, Mizuno A, et al. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim-based database. Int J Cardiol. 2019;280:104\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.049.","journal-title":"Int J Cardiol"},{"key":"1989_CR70","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/ajhp\/62.6.606","volume":"62","author":"KM O\u2019Dell","year":"2005","unstructured":"O\u2019Dell KM, Kalus JS, Kucukarslan S, Czerska B. Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. Am J Health-Syst Pharm. 2005;62:606\u20139. https:\/\/doi.org\/10.1093\/ajhp\/62.6.606.","journal-title":"Am J Health-Syst Pharm"},{"key":"1989_CR71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00246-006-0064-6","volume":"28","author":"EW Reynolds","year":"2007","unstructured":"Reynolds EW, Conely ET, Vranicar M. Nesiritide for the Treatment of Pulmonary Hypertension and Cor Pulmonale in an Infant. Pediatr Cardiol. 2007;28:229\u201333. https:\/\/doi.org\/10.1007\/s00246-006-0064-6.","journal-title":"Pediatr Cardiol"},{"key":"1989_CR72","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1161\/HYPERTENSIONAHA.121.17159","volume":"78","author":"HH Chen","year":"2021","unstructured":"Chen HH, Wan S-H, Iyer SR, Cannone V, Sangaralingham SJ, Nuetel J, et al. First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension. Hypertension. 2021;78:1859\u201367. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17159.","journal-title":"Hypertension"},{"key":"1989_CR73","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1161\/01.CIR.98.24.2760","volume":"98","author":"M Tajima","year":"1998","unstructured":"Tajima M, Bartunek J, Weinberg EO, Ito N, Lorell BH. Atrial Natriuretic Peptide Has Different Effects on Contractility and Intracellular pH in Normal and Hypertrophied Myocytes From Pressure-Overloaded Hearts. Circulation. 1998;98:2760\u20134. https:\/\/doi.org\/10.1161\/01.CIR.98.24.2760.","journal-title":"Circulation"},{"key":"1989_CR74","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.4065\/70.10.1015","volume":"70","author":"S Oparil","year":"1995","unstructured":"Oparil S. The Elusive Role of Atrial Natriuretic Peptide in Hypertension. Mayo Clin Proc. 1995;70:1015\u20137. https:\/\/doi.org\/10.4065\/70.10.1015.","journal-title":"Mayo Clin Proc"},{"key":"1989_CR75","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","volume":"10","author":"EG Bevan","year":"1992","unstructured":"Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, et al. Candoxatril, a neutral endopeptidase inhibitor. J Hypertens. 1992;10:607\u201314. https:\/\/doi.org\/10.1097\/00004872-199207000-00002.","journal-title":"J Hypertens"},{"key":"1989_CR76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1755-5922.12053","volume":"32","author":"JR Dalzell","year":"2014","unstructured":"Dalzell JR, Seed A, Berry C, Whelan CJ, Petrie MC, Padmanabhan N, et al. Effects of Neutral Endopeptidase (Neprilysin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat. Cardiovasc Ther. 2014;32:13\u201318. https:\/\/doi.org\/10.1111\/1755-5922.12053.","journal-title":"Cardiovasc Ther"},{"key":"1989_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11897-017-0327-y","volume":"14","author":"E Riddell","year":"2017","unstructured":"Riddell E, Vader JM. Potential Expanded Indications for Neprilysin Inhibitors. Curr Heart Fail Rep. 2017;14:134\u201345. https:\/\/doi.org\/10.1007\/s11897-017-0327-y.","journal-title":"Curr Heart Fail Rep"},{"key":"1989_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pharmthera.2014.05.002","volume":"144","author":"TG von Lueder","year":"2014","unstructured":"von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharm Ther. 2014;144:41\u201349. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.05.002.","journal-title":"Pharm Ther"},{"key":"1989_CR79","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1007\/s11906-001-0103-x","volume":"3","author":"O Vesterqvist","year":"2001","unstructured":"Vesterqvist O, Reeves RA. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and angiotensin-converting enzyme activity in humans. Curr Hypertens Rep. 2001;3:S22\u2013S27. https:\/\/doi.org\/10.1007\/s11906-001-0103-x.","journal-title":"Curr Hypertens Rep"},{"key":"1989_CR80","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"J Kostis","year":"2004","unstructured":"Kostis J. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103\u201311. https:\/\/doi.org\/10.1016\/j.amjhyper.2003.09.014.","journal-title":"Am J Hypertens"},{"key":"1989_CR81","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","volume":"36","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015;36:1967\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehv142.","journal-title":"Eur Heart J"},{"key":"1989_CR82","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2125.2003.01888.x","volume":"56","author":"W Liao","year":"2003","unstructured":"Liao W, Vesterqvist O, Delaney C, Jemal M, Ferreira I, Ford N, et al. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. Br J Clin Pharm. 2003;56:395\u2013406. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01888.x.","journal-title":"Br J Clin Pharm"},{"key":"1989_CR83","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.tetlet.2011.11.029","volume":"53","author":"L Feng","year":"2012","unstructured":"Feng L, Karpinski PH, Sutton P, Liu Y, Hook DF, Hu B, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53:275\u20136. https:\/\/doi.org\/10.1016\/j.tetlet.2011.11.029.","journal-title":"Tetrahedron Lett"},{"key":"1989_CR84","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/jm00010a014","volume":"38","author":"GM Ksander","year":"1995","unstructured":"Ksander GM, Ghai RD, deJesus R, Diefenbacher C, Yuan A, Berry C, et al. Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors. J Med Chem. 1995;38:1689\u20131700. https:\/\/doi.org\/10.1021\/jm00010a014.","journal-title":"J Med Chem"},{"key":"1989_CR85","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","volume":"14","author":"DJ Campbell","year":"2017","unstructured":"Campbell DJ. Long-term neprilysin inhibition \u2014 implications for ARNIs. Nat Rev Cardiol. 2017;14:171\u201386. https:\/\/doi.org\/10.1038\/nrcardio.2016.200.","journal-title":"Nat Rev Cardiol"},{"key":"1989_CR86","doi-asserted-by":"publisher","unstructured":"Gu J, Noe A, Chandra P, Al\u2010Fayoumi S, Ligueros\u2010Saylan M, Sarangapani R, et al. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual\u2010Acting Angiotensin Receptor\u2014Neprilysin Inhibitor (ARNi). J Clin Pharmacol. 2010;50:401\u201314. https:\/\/doi.org\/10.1177\/0091270009343932.","DOI":"10.1177\/0091270009343932"},{"key":"1989_CR87","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jcph.571","volume":"56","author":"L Gan","year":"2016","unstructured":"Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56:78\u201386. https:\/\/doi.org\/10.1002\/jcph.571.","journal-title":"J Clin Pharmacol"},{"key":"1989_CR88","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jch.14189","volume":"23","author":"M Sato","year":"2021","unstructured":"Sato M, Takahashi M, Kario K. Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary. J Clin Hypertens. 2021;23:692\u20135. https:\/\/doi.org\/10.1111\/jch.14189.","journal-title":"J Clin Hypertens"},{"key":"1989_CR89","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","volume":"264","author":"V Shi","year":"2018","unstructured":"Shi V, Senni M, Streefkerk H, Modgill V, Zhou W, Kaplan A. Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int J Cardiol. 2018;264:118\u201323. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.121.","journal-title":"Int J Cardiol"},{"key":"1989_CR90","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2022.10.033","volume":"81","author":"E Eworuke","year":"2023","unstructured":"Eworuke E, Welch EC, Haug N, Horgan C, Lee HS, Zhao Y, et al. Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors. J Am Coll Cardiol. 2023;81:321\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.033.","journal-title":"J Am Coll Cardiol"},{"key":"1989_CR91","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/ddg.15154","volume":"21","author":"R Lochbaum","year":"2023","unstructured":"Lochbaum R, Hoffmann TK, Greve J, Hahn J. Concomitant medication in patients with bradykinin\u2010mediated angioedema \u2013 there\u2019s more than ACE inhibitors. JDDG. 2023;21:1283\u20139. https:\/\/doi.org\/10.1111\/ddg.15154.","journal-title":"JDDG"},{"key":"1989_CR92","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40256-020-00445-7","volume":"21","author":"J Galo","year":"2021","unstructured":"Galo J, Celli D, Colombo R. Effect of Sacubitril\/Valsartan on Neurocognitive Function: Current Status and Future Directions. Am J Cardiovascular Drugs. 2021;21:267\u201370. https:\/\/doi.org\/10.1007\/s40256-020-00445-7.","journal-title":"Am J Cardiovascular Drugs"},{"key":"1989_CR93","doi-asserted-by":"publisher","unstructured":"Krittanawong C, Kitai T. Pharmacogenomics of angiotensin receptor\/neprilysin inhibitor and its long\u2010term side effects. Cardiovasc Ther. 2017;35. https:\/\/doi.org\/10.1111\/1755-5922.12272.","DOI":"10.1111\/1755-5922.12272"},{"key":"1989_CR94","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","volume":"8","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin Inhibitors in Heart Failure. JACC Basic Transl Sci. 2023;8:88\u2013105. https:\/\/doi.org\/10.1016\/j.jacbts.2022.05.010.","journal-title":"JACC Basic Transl Sci"},{"key":"1989_CR95","doi-asserted-by":"publisher","first-page":"7961","DOI":"10.2147\/IJGM.S295467","volume":"15","author":"JJ Cuthbert","year":"2022","unstructured":"Cuthbert JJ, Pellicori P, Clark AL. Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges. Int J Gen Med. 2022;15:7961\u201375. https:\/\/doi.org\/10.2147\/IJGM.S295467.","journal-title":"Int J Gen Med"},{"key":"1989_CR96","doi-asserted-by":"publisher","unstructured":"Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, et al. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON\u2010HF. J Am Heart Assoc. 2021;10. https:\/\/doi.org\/10.1161\/JAHA.121.021494.","DOI":"10.1161\/JAHA.121.021494"},{"key":"1989_CR97","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5603\/ARM.2018.0041","volume":"86","author":"E Siniorakis","year":"2018","unstructured":"Siniorakis E, Arvanitakis S, Elkouris M, Kalogirou S, Veldekis D, Limberi S. Chronic Obstructive Pulmonary Disease and Sacubitril: Explore the Role of Neprilysin before Its Inhibition. Adv Respir Med. 2018;86:255\u20136. https:\/\/doi.org\/10.5603\/ARM.2018.0041.","journal-title":"Adv Respir Med"},{"key":"1989_CR98","doi-asserted-by":"publisher","unstructured":"Gori M, Januzzi JL, D\u2019Elia E, Lorini FL, Senni M. Rationale for and Practical Use of Sacubitril\/Valsartan in the Patient\u2019s Journey with Heart Failure and Reduced Ejection Fraction. Card Fail Rev. 2021;7. https:\/\/doi.org\/10.15420\/cfr.2020.25.","DOI":"10.15420\/cfr.2020.25"},{"key":"1989_CR99","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.31838\/srp.2020.6.179","volume":"11","author":"C Shahidah","year":"2020","unstructured":"Shahidah C. & Azmi, Nurul & Arifin, Siti Roshaidai & amirruddin, salman. Valsartan induced exanthematous macular skin lesions. Sys Rev Pharm. 2020;11:1234\u20135. https:\/\/doi.org\/10.31838\/srp.2020.6.179.","journal-title":"Sys Rev Pharm"},{"key":"1989_CR100","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jacc.2016.12.043","volume":"69","author":"C Krittanawong","year":"2017","unstructured":"Krittanawong C, Kitai T. The Head and the Heart. J Am Coll Cardiol. 2017;69:1879\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.043.","journal-title":"J Am Coll Cardiol"},{"key":"1989_CR101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers15010312","volume":"15","author":"AM Sobiborowicz-Sadowska","year":"2023","unstructured":"Sobiborowicz-Sadowska AM, Kami\u0144ska K, Cudnoch-J\u0119drzejewska A. Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers. 2023;15:312. https:\/\/doi.org\/10.3390\/cancers15010312.","journal-title":"Cancers"},{"key":"1989_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00115-w","volume":"7","author":"A Mecinaj","year":"2021","unstructured":"Mecinaj A, Gulati G, Heck S, Holte E, Fagerland M, Larsen A, et al. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardio Oncol. 2021;7:33. https:\/\/doi.org\/10.1186\/s40959-021-00115-w.","journal-title":"Cardio Oncol"},{"key":"1989_CR103","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s00059-018-4683-5","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. Cognitive performance of patients with chronic heart failure on sacubitril\/valsartan. Herz. 2019;44:534\u201340. https:\/\/doi.org\/10.1007\/s00059-018-4683-5.","journal-title":"Herz"},{"key":"1989_CR104","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3233\/JAD-142463","volume":"44","author":"M H\u00fcttenrauch","year":"2015","unstructured":"H\u00fcttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O. Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer\u2019s Disease. J Alzheimers Dis. 2015;44:1291\u2013302. https:\/\/doi.org\/10.3233\/JAD-142463.","journal-title":"J Alzheimers Dis"},{"key":"1989_CR105","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"1989_CR106","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.taap.2017.03.014","volume":"323","author":"HA Schoenfeld","year":"2017","unstructured":"Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril\/valsartan, on central nervous system amyloid-\u03b2 concentrations and clearance in the cynomolgus monkey. Toxicol Appl Pharm. 2017;323:53\u201365. https:\/\/doi.org\/10.1016\/j.taap.2017.03.014.","journal-title":"Toxicol Appl Pharm"},{"key":"1989_CR107","doi-asserted-by":"publisher","unstructured":"Ali NH, Al\u2010Kuraishy HM, Al\u2010Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, et al. Neprilysin inhibitors and risk of Alzheimer\u2019s disease: A future perspective. J Cell Mol Med. 2024;28. https:\/\/doi.org\/10.1111\/jcmm.17993.","DOI":"10.1111\/jcmm.17993"},{"key":"1989_CR108","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.brainres.2013.05.045","volume":"1529","author":"MH Park","year":"2013","unstructured":"Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park J-S, et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer\u2019s disease mice. Brain Res. 2013;1529:113\u201324. https:\/\/doi.org\/10.1016\/j.brainres.2013.05.045.","journal-title":"Brain Res"},{"key":"1989_CR109","doi-asserted-by":"publisher","first-page":"e16575","DOI":"10.1371\/journal.pone.0016575","volume":"6","author":"B Spencer","year":"2011","unstructured":"Spencer B, Marr RA, Gindi R, Potkar R, Michael S, Adame A, et al. Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces A\u03b2 Toxicity in a Mouse Model of Alzheimer\u2019s Disease. PLoS One. 2011;6:e16575. https:\/\/doi.org\/10.1371\/journal.pone.0016575.","journal-title":"PLoS One"},{"key":"1989_CR110","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41371-023-00851-9","volume":"37","author":"R Mitsuno","year":"2023","unstructured":"Mitsuno R, Uchiyama K, Nakayama T, Takahashi R, Yoshimoto N, Yamaguchi S, et al. Comparison of the effects of angiotensin receptor\u2013neprilysin inhibitors and thiazide diuretic\/renin\u2013angiotensin system inhibitor combination therapy in hypertensive patients: a retrospective cohort study. J Hum Hypertens. 2023;37:1049\u201355. https:\/\/doi.org\/10.1038\/s41371-023-00851-9.","journal-title":"J Hum Hypertens"},{"key":"1989_CR111","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jch.14120","volume":"23","author":"DS\u2010H Lin","year":"2021","unstructured":"Lin DS\u2010H, Wang T, Buranakitjaroen P, Chen C, Cheng H, Chia YC, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe. J Clin Hypertens. 2021;23:556\u201367. https:\/\/doi.org\/10.1111\/jch.14120.","journal-title":"J Clin Hypertens"},{"key":"1989_CR112","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"B Zhou","year":"2021","unstructured":"Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1.","journal-title":"Lancet"},{"key":"1989_CR113","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/jcdd9030072","volume":"9","author":"P Verdecchia","year":"2022","unstructured":"Verdecchia P, Cavallini C, Angeli F. Advances in the Treatment Strategies in Hypertension: Present and Future. J Cardiovasc Dev Dis. 2022;9:72. https:\/\/doi.org\/10.3390\/jcdd9030072.","journal-title":"J Cardiovasc Dev Dis"},{"key":"1989_CR114","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","volume":"116","author":"S Oparil","year":"2015","unstructured":"Oparil S, Schmieder RE. New Approaches in the Treatment of Hypertension. Circ Res. 2015;116:1074\u201395. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303603.","journal-title":"Circ Res"},{"key":"1989_CR115","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.3390\/jcm12175495","volume":"12","author":"S Kowalski","year":"2023","unstructured":"Kowalski S, Goniewicz K, Moskal A, Al-Wathinani AM, Goniewicz M. Symptoms in Hypertensive Patients Presented to the Emergency Medical Service: A Comprehensive Retrospective Analysis in Clinical Settings. J Clin Med. 2023;12:5495. https:\/\/doi.org\/10.3390\/jcm12175495.","journal-title":"J Clin Med"},{"key":"1989_CR116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/03007995.2024.2317433","volume":"40","author":"H-P Marti","year":"2024","unstructured":"Marti H-P, Pav\u00eda L\u00f3pez AA, Schwartzmann P. Safety and tolerability of \u03b2-blockers: importance of cardioselectivity. Curr Med Res Opin. 2024;40:55\u201362. https:\/\/doi.org\/10.1080\/03007995.2024.2317433.","journal-title":"Curr Med Res Opin"},{"key":"1989_CR117","doi-asserted-by":"publisher","first-page":"e24655","DOI":"10.1016\/j.heliyon.2024.e24655","volume":"10","author":"DL Silva-Velasco","year":"2024","unstructured":"Silva-Velasco DL, Cervantes-P\u00e9rez LG, S\u00e1nchez-Mendoza A. ACE inhibitors and their interaction with systems and molecules involved in metabolism. Heliyon. 2024;10:e24655. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24655.","journal-title":"Heliyon"},{"key":"1989_CR118","doi-asserted-by":"publisher","unstructured":"Acharya KR, Gregory KS, Sturrock ED. Advances in the structural basis for angiotensin-1 converting enzyme (ACE) inhibitors. Biosci Rep. 2024;44. https:\/\/doi.org\/10.1042\/BSR20240130.","DOI":"10.1042\/BSR20240130"},{"key":"1989_CR119","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","volume":"78","author":"R Chen","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension. 2021;78:591\u2013603. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16667.","journal-title":"Hypertension"},{"key":"1989_CR120","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5152\/TurkThoracJ.2018.18014","volume":"20","author":"I Yilmaz","year":"2019","unstructured":"Yilmaz I. Angiotensin-Converting Enzyme Inhibitors Induce Cough. Turk Thorac J. 2019;20:36\u201342. https:\/\/doi.org\/10.5152\/TurkThoracJ.2018.18014.","journal-title":"Turk Thorac J"},{"key":"1989_CR121","doi-asserted-by":"crossref","unstructured":"Claude A. Diuretics. In: Pharmacology in Veterinary Anesthesia and Analgesia. Hoboken, New Jersey, USA: Wiley; 2024. p. 315\u201323.","DOI":"10.1002\/9781118975169.ch24"},{"key":"1989_CR122","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2016.02.031","volume":"67","author":"D Mavridis","year":"2016","unstructured":"Mavridis D, Palmer SC, Strippoli GFM. Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Am J Kidney Dis. 2016;67:713\u20135. https:\/\/doi.org\/10.1053\/j.ajkd.2016.02.031.","journal-title":"Am J Kidney Dis"},{"key":"1989_CR123","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2125.2008.03234.x","volume":"66","author":"G Novo","year":"2008","unstructured":"Novo G, Guttilla D, Fazio G, Cooper D, Novo S. The role of the renin\u2013angiotensin system in atrial fibrillation and the therapeutic effects of ACE\u2010Is and ARBS. Br J Clin Pharm. 2008;66:345\u201351. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03234.x.","journal-title":"Br J Clin Pharm"},{"key":"1989_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04910-6","volume":"28","author":"DE Leisman","year":"2024","unstructured":"Leisman DE, Handisides DR, Busse LW, Chappell MC, Chawla LS, Filbin MR, et al. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock. Crit Care. 2024;28:130. https:\/\/doi.org\/10.1186\/s13054-024-04910-6.","journal-title":"Crit Care"},{"key":"1989_CR125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1586\/14779072.6.5.759","volume":"6","author":"K Kolasinska-Malkowska","year":"2008","unstructured":"Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications. Expert Rev Cardiovasc Ther. 2008;6:759\u201371. https:\/\/doi.org\/10.1586\/14779072.6.5.759.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1989_CR126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1524-6175.2005.04140.x","volume":"8","author":"DA Sica","year":"2006","unstructured":"Sica DA. Pharmacotherapy Review: Calcium Channel Blockers. J Clin Hypertens. 2006;8:53\u201356. https:\/\/doi.org\/10.1111\/j.1524-6175.2005.04140.x.","journal-title":"J Clin Hypertens"},{"key":"1989_CR127","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.3390\/cimb46070377","volume":"46","author":"KE Jones","year":"2024","unstructured":"Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, et al. The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations. Curr Issues Mol Biol. 2024;46:6315\u201327. https:\/\/doi.org\/10.3390\/cimb46070377.","journal-title":"Curr Issues Mol Biol"},{"key":"1989_CR128","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jch.14436","volume":"24","author":"L Liang","year":"2022","unstructured":"Liang L, Kung JY, Mitchelmore B, Cave A, Banh HL. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta\u2010analysis. J Clin Hypertens. 2022;24:536\u201354. https:\/\/doi.org\/10.1111\/jch.14436.","journal-title":"J Clin Hypertens"},{"key":"1989_CR129","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ijcard.2014.08.032","volume":"176","author":"M Volpe","year":"2014","unstructured":"Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176:630\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2014.08.032.","journal-title":"Int J Cardiol"},{"key":"1989_CR130","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJM199807303390507","volume":"339","author":"FH Epstein","year":"1998","unstructured":"Epstein FH, Levin ER, Gardner DG, Samson WK. Natriuretic Peptides. N Engl J Med. 1998;339:321\u20138. https:\/\/doi.org\/10.1056\/NEJM199807303390507.","journal-title":"N Engl J Med"},{"key":"1989_CR131","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/ehjcvp\/pvv040","volume":"2","author":"CYW Lee","year":"2016","unstructured":"Lee CYW, Huntley BK, McCormick DJ, Ichiki T, Sangaralingham SJ, Lisy O, et al. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother. 2016;2:98\u2013105. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv040.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1989_CR132","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4330\/wjc.v13.i8.325","volume":"13","author":"D Usuda","year":"2021","unstructured":"Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, et al. Angiotensin receptor blocker neprilysin inhibitors. World J Cardiol. 2021;13:325\u201339. https:\/\/doi.org\/10.4330\/wjc.v13.i8.325.","journal-title":"World J Cardiol"},{"key":"1989_CR133","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11906-016-0694-x","volume":"18","author":"E Uijl","year":"2016","unstructured":"Uijl E, Roksnoer LCW, Hoorn EJ, Danser AHJ. From ARB to ARNI in Cardiovascular Control. Curr Hypertens Rep. 2016;18:86. https:\/\/doi.org\/10.1007\/s11906-016-0694-x.","journal-title":"Curr Hypertens Rep"},{"key":"1989_CR134","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","volume":"68","author":"A Bayes-Genis","year":"2016","unstructured":"Bayes-Genis A, Barallat J, Richards AM. A Test in Context: Neprilysin. J Am Coll Cardiol. 2016;68:639\u201353. https:\/\/doi.org\/10.1016\/j.jacc.2016.04.060.","journal-title":"J Am Coll Cardiol"},{"key":"1989_CR135","first-page":"341","volume":"101","author":"DK Smith","year":"2020","unstructured":"Smith DK, Lennon RP, Carlsgaard PB. Managing Hypertension Using Combination Therapy. Am Fam Physician. 2020;101:341\u20139.","journal-title":"Am Fam Physician"},{"key":"1989_CR136","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, D\u00fcngen H-D, Lam CSP, Lefkowitz MP, et al. Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42:3741\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehab499.","journal-title":"Eur Heart J"},{"key":"1989_CR137","doi-asserted-by":"crossref","unstructured":"Barbieri K, Potter LR. Natriuretic Peptides, Their Receptors and Therapeutic Applications. In Encyclopedia of Biological Chemistry. Amsterdam, Netherlands: Elsevier; 2013. p. 225\u20138.","DOI":"10.1016\/B978-0-12-378630-2.00402-3"},{"key":"1989_CR138","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","volume":"69","author":"T Nishikimi","year":"2006","unstructured":"Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69:318\u201328. https:\/\/doi.org\/10.1016\/j.cardiores.2005.10.001.","journal-title":"Cardiovasc Res"},{"key":"1989_CR139","doi-asserted-by":"publisher","first-page":"14415","DOI":"10.3390\/ijms232214415","volume":"23","author":"R Sarzani","year":"2022","unstructured":"Sarzani R, Allevi M, Di Pentima C, Schiavi P, Spannella F, Giulietti F. Role of Cardiac Natriuretic Peptides in Heart Structure and Function. Int J Mol Sci. 2022;23:14415. https:\/\/doi.org\/10.3390\/ijms232214415.","journal-title":"Int J Mol Sci"},{"key":"1989_CR140","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00395-013-0347-z","volume":"108","author":"M Jacob","year":"2013","unstructured":"Jacob M, Saller T, Chappell D, Rehm M, Welsch U, Becker BF. Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability. Basic Res Cardiol. 2013;108:347. https:\/\/doi.org\/10.1007\/s00395-013-0347-z.","journal-title":"Basic Res Cardiol"},{"key":"1989_CR141","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1161\/01.HYP.37.4.1179","volume":"37","author":"MLH Honing","year":"2001","unstructured":"Honing MLH, Smits P, Morrison PJ, Burnett JC, Rabelink TJ. C-Type Natriuretic Peptide\u2013Induced Vasodilation Is Dependent On Hyperpolarization in Human Forearm Resistance Vessels. Hypertension. 2001;37:1179\u201383. https:\/\/doi.org\/10.1161\/01.HYP.37.4.1179.","journal-title":"Hypertension"},{"key":"1989_CR142","doi-asserted-by":"publisher","first-page":"137","DOI":"10.59249\/NCST6937","volume":"96","author":"M Samad","year":"2023","unstructured":"Samad M, Malempati S, Restini CBA. Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions. Yale J Biol Med. 2023;96:137\u201349. https:\/\/doi.org\/10.59249\/NCST6937.","journal-title":"Yale J Biol Med"},{"key":"1989_CR143","doi-asserted-by":"publisher","first-page":"A71","DOI":"10.1186\/2050-6511-16-S1-A71","volume":"16","author":"H Nakagawa","year":"2015","unstructured":"Nakagawa H, Nakada Y, Saito Y. Natriuretic peptides regulate sympathetic nervous activity independent of mineralocorticoid receptor. BMC Pharm Toxicol. 2015;16:A71. https:\/\/doi.org\/10.1186\/2050-6511-16-S1-A71.","journal-title":"BMC Pharm Toxicol"},{"key":"1989_CR144","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2004.04.004","volume":"102","author":"Z Abassi","year":"2004","unstructured":"Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharm Ther. 2004;102:223\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2004.04.004.","journal-title":"Pharm Ther"},{"key":"1989_CR145","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/01.RES.78.4.606","volume":"78","author":"Y Komatsu","year":"1996","unstructured":"Komatsu Y, Itoh H, Suga S, Ogawa Y, Hama N, Kishimoto I, et al. Regulation of Endothelial Production of C-Type Natriuretic Peptide in Coculture With Vascular Smooth Muscle Cells. Circ Res. 1996;78:606\u201314. https:\/\/doi.org\/10.1161\/01.RES.78.4.606.","journal-title":"Circ Res"},{"key":"1989_CR146","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/biology11091351","volume":"11","author":"T Tokudome","year":"2022","unstructured":"Tokudome T, Otani K. Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide. Biology. 2022;11:1351. https:\/\/doi.org\/10.3390\/biology11091351.","journal-title":"Biology"},{"key":"1989_CR147","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1210\/en.2008-1360","volume":"150","author":"K Sabrane","year":"2009","unstructured":"Sabrane K, Kruse M-N, Gazinski A, Kuhn M. Chronic Endothelium-Dependent Regulation of Arterial Blood Pressure by Atrial Natriuretic Peptide: Role of Nitric Oxide and Endothelin-1. Endocrinology. 2009;150:2382\u20137. https:\/\/doi.org\/10.1210\/en.2008-1360.","journal-title":"Endocrinology"},{"key":"1989_CR148","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ajh\/hpx111","volume":"30","author":"O Supasyndh","year":"2017","unstructured":"Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H. Efficacy and Safety of Sacubitril\/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (\u226565 Years) With Systolic Hypertension. Am J Hypertens. 2017;30:1163\u20139. https:\/\/doi.org\/10.1093\/ajh\/hpx111.","journal-title":"Am J Hypertens"},{"key":"1989_CR149","doi-asserted-by":"publisher","first-page":"030006052211384","DOI":"10.1177\/03000605221138480","volume":"50","author":"T Imamura","year":"2022","unstructured":"Imamura T, Kinugawa K. Effect of add-on sacubitril\/valsartan on the left ventricular hypertrophy of a patient with hypertension. J Int Med Res. 2022;50:030006052211384. https:\/\/doi.org\/10.1177\/03000605221138480.","journal-title":"J Int Med Res"},{"key":"1989_CR150","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/j.ekir.2023.02.364","volume":"8","author":"J CAIRNS","year":"2023","unstructured":"CAIRNS J, Bonor E, Banerjee D. WCN23-1182 safety and efficacy of sacubitril-valsartan in chronic kidney disease and dialysis patients with heart failure. Kidney Int Rep. 2023;8:S161\u2013S162. https:\/\/doi.org\/10.1016\/j.ekir.2023.02.364.","journal-title":"Kidney Int Rep"},{"key":"1989_CR151","doi-asserted-by":"publisher","unstructured":"Almansouri NE, Bakkannavar S, Faheem Y, Jaiswal A, Shergill K, Boppana K, et al. Efficacy of Angiotensin Receptor-Neprilysin Inhibitor and Its Renal Outcome in Heart Failure Patients: A Systematic Review of Randomized Clinical Trials. Cureus. 2024; https:\/\/doi.org\/10.7759\/cureus.54501.","DOI":"10.7759\/cureus.54501"},{"key":"1989_CR152","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/1074248419838503","volume":"24","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Ma R, Yu X, Li N, Zhao X, Yu J. AHU377+Valsartan (LCZ696) Modulates Renin\u2013Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan. J Cardiovasc Pharm Ther. 2019;24:450\u20139. https:\/\/doi.org\/10.1177\/1074248419838503.","journal-title":"J Cardiovasc Pharm Ther"},{"key":"1989_CR153","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/13543784.2013.797963","volume":"22","author":"AA Voors","year":"2013","unstructured":"Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs. 2013;22:1041\u20137. https:\/\/doi.org\/10.1517\/13543784.2013.797963.","journal-title":"Expert Opin Investig Drugs"},{"key":"1989_CR154","doi-asserted-by":"publisher","first-page":"e16093","DOI":"10.1097\/MD.0000000000016093","volume":"98","author":"Q Li","year":"2019","unstructured":"Li Q, Li L, Wang F, Zhang W, Guo Y, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension. Medicine. 2019;98:e16093 https:\/\/doi.org\/10.1097\/MD.0000000000016093.","journal-title":"Medicine"},{"key":"1989_CR155","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/hr.2016.151","volume":"40","author":"O Supasyndh","year":"2017","unstructured":"Supasyndh O, Sun N, Kario K, Hafeez K, Zhang J. Long-term (52-week) safety and efficacy of Sacubitril\/valsartan in Asian patients with hypertension. Hypertens Res. 2017;40:472\u20136. https:\/\/doi.org\/10.1038\/hr.2016.151.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01989-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:41:17Z","timestamp":1736138477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01989-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01989-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}